Integrin β1-Mediated Cell⁻Cell Adhesion Augments Metformin-Induced Anoikis

Area of Science:

• Cancer Biology
• Pharmacology
• Cellular Adhesion Mechanisms

Background:

• Cell-cell adhesion is crucial for regulating cancer cell proliferation, migration, survival, and drug sensitivity.
• Metformin, a common type 2 diabetes medication, exhibits known anti-cancer properties.
• The influence of cell-cell adhesion on metformin's anti-cancer effects remains largely unexplored.

Purpose of the Study:

• To investigate the role of cell-cell adhesion in metformin's anti-cancer activity.
• To elucidate the molecular mechanisms underlying metformin-induced changes in cell adhesion.

Main Methods:

• Microscopy and Fluorescence-Activated Cell Sorting (FACS) analyses to assess cell aggregation and anoikis.
• Western blot and quantitative Polymerase Chain Reaction (qPCR) to analyze protein and gene expression.
• Integrin β1 gene silencing and investigation of the role of ΔNp63α.

Main Results:

• Metformin treatment induced cancer cell-cell adhesion, evidenced by increased cell aggregation and anoikis, particularly under glucose restriction.
• Metformin significantly upregulated the expression of integrin β1.
• Silencing integrin β1 diminished metformin-induced cell aggregation and anoikis; ΔNp63α was identified as a transcriptional suppressor of integrin β1.

Conclusions:

• Metformin's anti-cancer effects are partly mediated by inducing cell-cell adhesion through integrin β1 upregulation.
• Integrin β1-mediated cell adhesion and subsequent anoikis are critical components of metformin's anti-cancer mechanism.
• The p53 family member ΔNp63α plays a regulatory role in metformin's effect on integrin β1 expression.